The Avicena Group , Inc.

The Avicena Group, Inc. (OTCBB: AVGO) is a late stage, revenue generating biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/ III trial in ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's Disease). Near term, Avicena intends to initiate both a Phase III trial in Huntington's Disease and a Phase III trial in Parkinson's ( www.avicenagroup.com )